Oncogenex Files for IPO

Oncogenex Technologies Inc., a Vancouver-based drug company focused on cancer therapeutics, has filed for a $48 million IPO. It plans to trade on both the Nasdaq and TSX, with RBC Capital Markets serving as lead underwriter. Shareholders include Ventures West, BDC Venture Capital, GrowthWorks, HIG Capital and Milestone Medica Corp. www.oncogenex.ca< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />